Search

Corvus Pharmaceuticals Inc

Atidarymo kaina

12.97 -2.33

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.63

Max

13.32

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+137.42% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-261M

1.1B

Ankstesnė atidarymo kaina

15.3

Ankstesnė uždarymo kaina

12.97

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-28 23:56; UTC

Correlated Moves

Shares of T Rowe Price Group Inc declined in after-market trading, reversing a trend of higher closes over the previous three sessions.

2026-07-28 23:56; UTC

Krispy Kreme Inc shares are higher in after-market hours, reflecting broader market gains driven by strong earnings from Coca-Cola and UPS.

2026-07-28 23:56; UTC

Northern Trust Corp shares are trading lower in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

2026-07-28 23:56; UTC

Yelp Inc shares are higher in after-market hours, continuing a recent upward trend amid broader market gains driven by strong earnings from Coca-Cola and UPS.

2026-07-28 23:56; UTC

Correlated Moves

ProPetro Holding Corp shares rose during after-market hours, aligning with a 3.61% increase in the VanEck Oil Services ETF amid positive sector sentiment.

2026-07-28 23:56; UTC

Correlated Moves

Encore Capital Group shares rose in after-market hours, reflecting positive market sentiment. The Russell 2000 Index also increased, supporting investor confidence.

2026-07-28 23:56; UTC

Immunovant Inc shares higher in after-market trading, reflecting broader market strength amid positive earnings from companies like UPS and Coca-Cola.

2026-07-28 23:56; UTC

Palo Alto Networks shares rose in after-market trading, supported by broader market gains and strong earnings from companies like Coca-Cola and UPS.

2026-07-28 23:56; UTC

Carvana Co shares are lower in after-market trading, with no specific news identified to explain the decline. The stock reversed from earlier gains.

2026-07-28 23:56; UTC

Rollins Inc. shares rose slightly in after-market trading, with no specific news identified. Broader market gains were supported by strong earnings from UPS and Coca-Cola.

2026-07-28 23:56; UTC

Viasat Inc. shares rose in after-market trading, reflecting broader market strength from positive earnings reports, including those from Coca-Cola and UPS.

2026-07-28 23:56; UTC

News

Coursera Inc announced a $100 million investment in LearnVector, enhancing its AI strategy. Shares are trading higher during after-market hours.

2026-07-28 23:56; UTC

Correlated Moves

Pentair PLC's shares were roughly flat in after-market hours amid broader market gains driven by strong earnings from Coca-Cola and UPS.

2026-07-28 23:56; UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

2026-07-28 23:56; UTC

Microchip Technology Inc shares are lower in after-market trading, continuing a six-session decline amid a broader market rally driven by strong earnings from UPS.

2026-07-28 23:56; UTC

Correlated Moves

Vishay Intertechnology shares are lower in after-hours trading, continuing a decline seen since Tuesday. The stock remains below its 20-day moving average.

2026-07-28 23:56; UTC

Viavi Solutions Inc shares are lower in after-market trading. No specific news was identified to explain the decline amid broader market gains.

2026-07-28 23:56; UTC

Arista Networks Inc shares are lower in after-market hours. No specific news was identified for the decline, which follows three consecutive sessions of losses.

2026-07-28 23:56; UTC

Geo Group Inc shares are higher in after-market hours, supported by broader market strength from strong earnings reports, including those from UPS and Coca-Cola.

2026-07-28 23:56; UTC

Borgwarner Inc shares are higher in after-market trading, rebounding from an earlier dip amid broader market gains driven by strong earnings from UPS and Coca-Cola.

2026-07-28 23:52; UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher in after-market trading as the company surpasses a $5 trillion market capitalization ahead of its Q3 earnings report.

2026-07-28 23:52; UTC

OUTFRONT Media Inc shares are lower in after-market trading, declining since Tuesday's close despite three consecutive sessions of gains. No specific news was identified.

2026-07-28 23:52; UTC

Mexican Consumer Confidence Index Set for Release Amid Global Mixed Signals and Local Pessimism, Anticipated to Reflect Economic Sentiment on August 4, 2026.

2026-07-28 23:52; UTC

Brazil's Industrial Production MoM data for June 2026 set to release on August 4, amid cautious market sentiment following May's unexpected decline.

2026-07-28 23:52; UTC

Brazil's Central Bank Faces Mixed Market Sentiment Ahead of August 2026 Interest Rate Decision Amid Inflation and Economic Concerns.

2026-07-28 23:52; UTC

Australia's Producer Price Inflation (PPI) set for July 31, with a projected 0.3% increase amid cautious inflation sentiment and potential interest rate hikes from the Reserve Bank of Australia.

2026-07-28 23:52; UTC

South Korea's S&P Global Manufacturing PMI set for August 3, with expectations of declining activity amid rising costs and significant stock market drops.

2026-07-28 23:52; UTC

China's Non-Manufacturing PMI set for July 31 release, forecasted at neutral 50.0 amid mixed economic sentiment and geopolitical tensions.

2026-07-28 23:52; UTC

China's NBS Manufacturing PMI forecasted to hold steady at 50.0, signaling stagnation amid mixed global manufacturing signals ahead of July 31st release.

2026-07-28 23:52; UTC

Social Media
News

Avis Budget Group shares lower in after-market trading following second-quarter results that missed expectations, with EPS of $0.98 against estimates of $1.91.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

137.42% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  137.42%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat